Andrew C.G. Porter

4.6k total citations
83 papers, 3.6k citations indexed

About

Andrew C.G. Porter is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Andrew C.G. Porter has authored 83 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Molecular Biology, 25 papers in Oncology and 15 papers in Genetics. Recurrent topics in Andrew C.G. Porter's work include DNA Repair Mechanisms (21 papers), CRISPR and Genetic Engineering (18 papers) and Cancer therapeutics and mechanisms (15 papers). Andrew C.G. Porter is often cited by papers focused on DNA Repair Mechanisms (21 papers), CRISPR and Genetic Engineering (18 papers) and Cancer therapeutics and mechanisms (15 papers). Andrew C.G. Porter collaborates with scholars based in United Kingdom, United States and Germany. Andrew C.G. Porter's co-authors include Jane E. Itzhaki, Dirk R. Gewert, Daniel O’Connor, Dario C. Altieri, Nathan R. Wall, Christine J. Farr, Rafael J. Yáñez‐Muñoz, Christopher S. Gilbert, Timothy C. Humphrey and Sara Ahrabi and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Andrew C.G. Porter

82 papers receiving 3.6k citations

Peers

Countries citing papers authored by Andrew C.G. Porter

Since Specialization

Citations

This map shows the geographic impact of Andrew C.G. Porter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew C.G. Porter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew C.G. Porter more than expected).

Fields of papers citing papers by Andrew C.G. Porter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew C.G. Porter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew C.G. Porter. The network helps show where Andrew C.G. Porter may publish in the future.

Co-authorship network of co-authors of Andrew C.G. Porter

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew C.G. Porter. A scholar is included among the top collaborators of Andrew C.G. Porter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew C.G. Porter. Andrew C.G. Porter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Proteomic Profiling of the Large‐Vessel Vasculitis Spectrum Identifying Shared Signatures of Innate Immune Activation and Stromal Remodeling 2025 ·Arthritis & Rheumatology ·(unknown), Erin Macdonald-Dunlop, (unknown), (unknown), (unknown), Shauna Masters, Andrew C.G. Porter, (unknown), Charis Pericleous, Andrew Hutchings, James Robinson, Taryn Youngstein, Raashid Luqmani, Justin C. Mason, Ann W Morgan, James E. Peters	1
2	Nuclear alpha-synuclein is present in the human brain and is modified in dementia with Lewy bodies 2022 ·Acta Neuropathologica Communications ·David J. Koss, Daniel Erskine, Andrew C.G. Porter, (unknown), (unknown), (unknown), (unknown), Johannes Attems, Tiago F. Outeiro	43
3	The Generation of a Comprehensive Spectral Library for the Analysis of the Guinea Pig Proteome by SWATH‐MS 2019 ·PROTEOMICS ·Paweł Palmowski, (unknown), G. Nicholas Europe‐Finner, (unknown), Andrew C.G. Porter, Achim Treumann, Michael J. Taggart	13
4	Kub5-Hera RPRD1B Deficiency Promotes “BRCAness” and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers 2018 ·Clinical Cancer Research ·Edward A. Motea, Farjana Fattah, Ling Xiao, Luc Girard, Amy Rommel, Julio C. Morales, Praveen Patidar, Yunyun Zhou, Andrew C.G. Porter, Yang Xie, John D. Minna, David A. Boothman	12
5	Efficient generation of laminated and light responsive retinal organoids for use in toxicological assays 2018 ·Investigative Ophthalmology & Visual Science ·Dean Hallam, Gerrit Hilgen, Birthe Dorgau, Min Yu, Lili Zhu, Sanja Bojić, Philip Hewitt, Michael Schmitt, Marianne Uteng, Stefan Kustermann, David Steel, Andrew C.G. Porter, Achim Treumann, Evelyne Sernagor, Lyle Armstrong, Majlinda Lako	1
6	Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint 2017 ·Nucleic Acids Research ·Toshiyuki Kozuki, Kenichi Chikamori, Marius Surleac, (unknown), Andrei‐José Petrescu, (unknown), Paul Elson, Gerald A. Hoeltge, Dale Grabowski, Andrew C.G. Porter, Ram Ganapathi, Mahrukh K. Ganapathi	23
7	Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma 2016 ·Journal of Biological Chemistry ·Daniel Beck, (unknown), Ruth Barber, Siân Evans, Larissa Lezina, (unknown), Matthew Blades, Richard Elliott, Christopher J. Lord, Alan Ashworth, Andrew C.G. Porter, Simon D. Wagner	12
8	Treatment with Gefitinib or Lapatinib Induces Drug Resistance through Downregulation of Topoisomerase IIα Expression 2013 ·Molecular Cancer Therapeutics ·Jaishree Bhosle, Konstantinos Kiakos, Andrew C.G. Porter, Jenny Wu, Andreas Makris, John A. Hartley, Daniel Hochhauser	9
9	Topoisomerase IIα-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin 2009 ·Molecular Cancer Therapeutics ·(unknown), Shiwei Deng, (unknown), Ute Gödtel‐Armbrust, Andrew C.G. Porter, Leszek Wojnowski	34
10	Depletion and Mutation of Topoisomerase II in Animal Cells 2009 ·Methods in molecular biology ·Andrew C.G. Porter	4
11	A nonsense mutation of PEPD in four Amish children with prolidase deficiency 2006 ·American Journal of Medical Genetics Part A ·Heng Wang, Biji T. Kurien, David Lundgren, (unknown), Kenneth M. Kaufman, David L. Miller, Andrew C.G. Porter, Anil D’Souza, (unknown), (unknown), Vera Hupertz, Douglas S. Kerr, Sadamu Kurono, Hiroyuki Matsumoto, R. Hal Scofield	21
12	Two Hands Make Light Work of Gene Modification 2005 ·Rejuvenation Research ·Andrew C.G. Porter	1
13	Hypothesis: transcript‐templated repair of DNA double‐strand breaks 2005 ·BioEssays ·(unknown), Andrew C.G. Porter	12
14	Mechanized Syringe Homogenization of Human and Animal Tissues 2004 ·Assay and Drug Development Technologies ·Biji T. Kurien, Andrew C.G. Porter, (unknown), Sadamu Kurono, Hiroyuki Matsumoto, R. Hal Scofield	3
15	Construction, Characterization, and Complementation of a Conditional-Lethal DNA Topoisomerase IIα Mutant Human Cell Line 2004 ·Molecular Biology of the Cell ·(unknown), Andrew C.G. Porter	116
16	Synchronization of Interphase Events Depends neither on Mitosis nor on cdk1 2003 ·Molecular Biology of the Cell ·(unknown), Shay Rotkopf, Asaf Hellman, Yosef Gruenbaum, Andrew C.G. Porter, Michael Brandeis	21
17	Repression of CDK1 and Other Genes with CDE and CHR Promoter Elements during DNA Damage-Induced G ₂ /M Arrest in Human Cells 2000 ·Molecular and Cellular Biology ·Christophe Badie, Jane E. Itzhaki, Matthew J. Sullivan, (unknown), Andrew C.G. Porter	75
18	Telomere directed fragmentation of mammalian chromosomes 1993 ·Nucleic Acids Research ·(unknown), Veronica J. Buckle, E.P. Evans, Andrew C.G. Porter, Derek Rout, Austin Smith, William R. Brown	124
19	Targeted breakage of a human chromosome mediated by cloned human telomeric DNA 1992 ·Nature Genetics ·Jane E. Itzhaki, (unknown), (unknown), Veronica J. Buckle, William R. Brown, Andrew C.G. Porter	71
20	Differential response of the human 6–16 and 9–27 genes to α and γ interferons 1991 ·Nucleic Acids Research ·Andrew M. Ackrill, (unknown), Christopher S. Gilbert, Dirk R. Gewert, Andrew C.G. Porter, (unknown), George R. Stark, Ian M. Kerr	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact